Mixtard 50 Penfill (Insulin Human)

• Mixtard 50 Penfill, a human insulin formulation, acts within the insulin‑dependent pathway to control blood glucose in diabetes.
• Type 1 diabetes mellitus: provides basal and prandial insulin to achieve target glycemic control.
• Type 2 diabetes mellitus: improves insulin deficiency and resistance, helping patients reach individualized glucose goals.
• Blood glucose management: reduces hyperglycemia episodes and supports overall metabolic stability.
• Prevention of acute hyperglycemic crises: maintains stable glucose levels, reducing the risk of ketoacidosis and hyperosmolar states.

• Insulin human binds to insulin receptors on muscle, adipose and hepatic cells, activating the receptor tyrosine kinase pathway. This promotes translocation of GLUT‑4 transporters, increasing glucose uptake, and suppresses hepatic gluconeogenesis. The resulting actions lower circulating glucose and provide both basal and post‑prandial insulin activity, mimicking physiological insulin secretion. The effect persists for several hours, allowing once‑ or twice‑daily dosing depending on the therapeutic regimen.

Insulin human may cause adverse reactions ranging from mild to severe.

Common Side Effects

• Hypoglycemia: low blood glucose episodes with symptoms such as sweating, tremor, or confusion.
• Injection site reactions: redness, swelling, or itching at the injection site.
• Weight gain: increase in body weight associated with improved glucose utilization.

Serious or Rare Side Effects

• Severe hypoglycemia: profound low glucose that can lead to seizures or loss of consciousness.
• Allergic reactions: rash, urticaria, or anaphylaxis requiring immediate medical attention.
• Insulin antibodies: formation of antibodies that may alter insulin action.

When using Mixtard 50 Penfill, several precautions should be observed to ensure safe and effective therapy.

• Blood glucose monitoring: check levels regularly to adjust dose as needed.
• Dose adjustment during illness: reduce or increase insulin based on carbohydrate intake and activity.
• Caution in renal or hepatic impairment: may require lower doses and closer monitoring.
• Avoid use in hypoglycemia: do not administer if blood glucose is already low.
• Pregnancy and lactation: considered safe (Category B) but use under medical supervision.
• Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Insulin human can interact with other medicines, altering its glucose‑lowering effect or increasing the risk of adverse events.

Major Interactions (Avoid)

• Beta‑blockers: may mask hypoglycemia symptoms, requiring careful monitoring.
• Sulfonylureas and meglitinides: additive glucose‑lowering effect can cause severe hypoglycemia.
• ACE inhibitors and ARBs: may potentiate insulin’s effect, increasing hypoglycemia risk.

Moderate Interactions (Monitor Closely)

• Corticosteroids: raise blood glucose, possibly necessitating higher insulin doses.
• Thiazide diuretics: can increase blood glucose modestly.
• Oral contraceptives: may slightly reduce insulin sensitivity.